Corporate ActionMay 8, 2026, 02:07 PM
ROKIT America Plans IPO of 2.63M Shares at $9.50 Midpoint
AI Summary
ROKIT America, Inc. filed an S-1/A for its initial public offering, proposing to sell 2,631,579 shares of common stock at an anticipated price range of $8.50 to $10.50 per share, with a midpoint of $9.50. The offering aims to raise approximately $25 million before expenses. The company reported significant revenue growth for its Reverse Aging Product (RAP) business, from $364,880 in 2020 to $7,430,152 in 2025, and achieved net income of $1,586,493 in 2025. ROKIT America is also expanding its Organ Regeneration Platform (ORP), which generated $130,000 in revenue from cartilage regeneration kits in Paraguay in 2025 and has components listed or cleared by regulatory authorities in the Americas.
Key Highlights
- Plans IPO of 2,631,579 common shares at an estimated $8.50-$10.50 per share.
- Assumed IPO price of $9.50 per share, targeting $25,000,000 total offering.
- Reported revenue growth from $364,880 in 2020 to $7,430,152 in 2025.
- Achieved net income of $1,586,493 in 2025 and $651,462 in 2024.
- Organ Regeneration Platform (ORP) generated $130,000 revenue in 2025 from Paraguay.
- Filed U.S. patent application for telomere-stabilizing formulations on September 30, 2025.
- Skin regeneration platform components are Class I listed or Class II cleared by FDA.